A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration Resistant Prostate Cancer Patients Who Are Chemotherapy-Naïve
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Asahi, Japan
-
Fukuoka, Japan
-
Gifu, Japan
-
Kanazawa, Japan
-
Kashiwa, Japan
-
Kita-Gun, Japan
-
Kuki, Japan
-
Kurashiki, Japan
-
Maebashi, Japan
-
Matsuyama, Japan
-
Mitaka, Japan
-
Niigata, Japan
-
Osaka, Japan
-
Osaka-Sayama, Japan
-
Sagamihara, Japan
-
Sakura, Japan
-
Sapporo, Japan
-
Yokohama, Japan
-
Yokosuka, Japan
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- In-patients or out-patients with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
- Have surgically or medically castrated, with testosterone levels of less than 50 nanogram per deciliter
- Have prostate-specific antigen (PSA) level of at least 5 nanogram per milliliter
- Be under PSA progression according to Prostate-Specific Antigen Working Group (PSAWG) eligibility criteria or objective progression by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria for participants with measurable disease after androgen deprivation
- Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1
Exclusion Criteria:
- Has received other hormonal therapy, including any dose of finasteride, dutasteride, any herbal product known to decrease PSA levels or any systemic corticosteroid within 4 weeks prior to Cycle 1 Day 1 or has received ketoconazole for prostate cancer
- Has received radiotherapy, chemotherapy (including estramustine) or immunotherapy (including provenge) within 4 weeks, or single fraction of palliative radiotherapy within 2 weeks prior to Cycle 1 Day 1
- Has had surgery or local prostatic intervention within 4 weeks prior to Cycle 1 Day 1. In addition, any clinically relevant sequel from the surgery must have resolved prior to Cycle 1 Day 1
- Has clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events, severe or unstable angina, or New York Heart Association (NYHA) Class 3 to 4 heart disease or cardiac ejection fraction measurement of less than 50 percent within 6 months prior to Cycle 1 Day 1
- Has uncontrolled hypertension (systolic blood pressure greater than or equal to 160 millimeter of mercury or diastolic blood pressure greater than or equal to 95 millimeter of mercury)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Abiraterone plus Prednisolone
Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
|
Abirateron wird oral in einer Dosierung von 1000 Milligramm (mg) pro Tag über 28-tägige Dosierungszyklen verabreicht, die bis zum Fortschreiten der Krankheit oder bis zu einer inakzeptablen Toxizität fortgesetzt werden.
Andere Namen:
Prednisolon wird oral als 5-mg-Tablette zweimal täglich über einen 28-tägigen Dosierungszyklus verabreicht, der bis zum Fortschreiten der Krankheit oder einer inakzeptablen Toxizität fortgesetzt wird.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of participants achieving Prostate-Specific Antigen (PSA) response up to 12 weeks
Zeitfenster: Baseline up to 12 weeks
|
The PSA response will be evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline up to 12 weeks after the first dose of study drug, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA.
|
Baseline up to 12 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of participants with Radiographic Objective Response
Zeitfenster: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 5 years
|
Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0.
The CR is disappearance of all lesions.
The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
|
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 5 years
|
|
Duration of Prostate-Specific Antigen (PSA) response
Zeitfenster: Baseline and Day 1 of each cycle up to 5 years
|
Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from Baseline by greater than or equal to 50 percent.
|
Baseline and Day 1 of each cycle up to 5 years
|
|
Percentage of participants achieving Prostate-Specific Antigen (PSA) response
Zeitfenster: Baseline and Day 1 of each cycle up to 5 years
|
The PSA response is decrease in PSA from Baseline by greater than or equal to 50 percent.
|
Baseline and Day 1 of each cycle up to 5 years
|
|
Clinical benefit
Zeitfenster: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle up to 5 years
|
Clinical Benefit is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) according to RECIST Version 1.0.
The CR is disappearance of all lesions.
The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
The SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease since treatment started.
|
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle up to 5 years
|
|
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score
Zeitfenster: Baseline, Day 1, 8, 15 and 22 of Cycle 1 and 2, and thereafter Day 1 and 15 of all cycles up to 5 years
|
The ECOG PS Score 0 versus 1, wherein 0 signifies fully active, able to carry all pre-disease performance without restriction and 1 signifies restriction in physically strenuous activity but ambulatory and able to carry out work on a light or sedentary nature, for example, light housework, office work.
|
Baseline, Day 1, 8, 15 and 22 of Cycle 1 and 2, and thereafter Day 1 and 15 of all cycles up to 5 years
|
|
Decline in Serum Prostate-Specific Antigen (PSA)
Zeitfenster: Baseline and Day 1 of each cycle up to 5 years
|
Decline in serum PSA according to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criterion, which is, 25 percent increase in PSA and an absolute increase in PSA level by 2 nanogram per milliliter or more, from Baseline which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA.
|
Baseline and Day 1 of each cycle up to 5 years
|
|
Overall survival
Zeitfenster: Every 3 months until death or up to 5 years
|
Overall survival is defined as the time interval from the date of first dose to date of death.
|
Every 3 months until death or up to 5 years
|
|
Prostate-Specific Antigen based Progression-free Survival (PSA-PFS)
Zeitfenster: Baseline and Day 1 of each cycle until first documented disease progression or up to 5 years
|
The PSA-PFS is defined as time to first PSA failure (that is, two consecutive increases in PSA of 50 percent and greater than or equal to 5 nanogram per milliliter, as per Prostate-Specific Antigen Working Group [PSAWG]criterion) or death .
|
Baseline and Day 1 of each cycle until first documented disease progression or up to 5 years
|
|
Radiographic Progression-free Survival (RAD-PFS)
Zeitfenster: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 5 years
|
The RAD-PFS is defined as time from randomization to the earliest objective evidence of radiographic progression or death due to any cause.
The RAD-PFS will be evaluated according to RECIST Version 1.0.
|
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 5 years
|
|
Percentage of participants with Circulating Tumor Cell (CTC) conversion
Zeitfenster: Day 1 of Cycle 2, 3, and 4
|
The CTC is the pharmacodynamic potential predictive biomarker for tumor sensitivity.
|
Day 1 of Cycle 2, 3, and 4
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Genitale Neubildungen, männlich
- Prostataerkrankungen
- Prostataneoplasmen
- Physiologische Wirkungen von Arzneimitteln
- Entzündungshemmende Mittel
- Antineoplastische Mittel
- Glukokortikoide
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Antineoplastische Mittel, hormonell
- Prednisolon
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CR017059
- JNJ-212082-JPN-201
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .